Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/92831
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Branford, S. | - |
dc.contributor.author | Yeung, D. | - |
dc.contributor.author | Ross, D. | - |
dc.contributor.author | Parker, W. | - |
dc.contributor.author | Braley, J. | - |
dc.contributor.author | Seymour, J. | - |
dc.contributor.author | Hughes, T. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Blood, 2014, vol.124, iss.21, pp.816-816 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.issn | 1528-0020 | - |
dc.identifier.uri | http://hdl.handle.net/2440/92831 | - |
dc.description.statementofresponsibility | Susan Branford, David T Yeung, David M Ross, Wendy T Parker, Jodi Braley, John F Seymour, and Timothy P. Hughes | - |
dc.language.iso | en | - |
dc.publisher | American Society of Hematology | - |
dc.rights | © 2014 by The American Society of Hematology | - |
dc.title | The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment | - |
dc.type | Conference item | - |
dc.contributor.conference | 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California) | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
dc.identifier.orcid | Yeung, D. [0000-0002-7558-9927] | - |
dc.identifier.orcid | Ross, D. [0000-0001-7171-2935] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.